Atrial Fibrillation (AF)NCT07483008
3D Printing Technology For Planning Left Atrial Appendage Occlusion
A study testing 3D-printed models of the left atrial appendage and Standard preoperative planning in people with Atrial Fibrillation (AF) and 3D Printing, run by Chinese University of Hong Kong at 1 site in Hong Kong.
Trial summary
Atrial fibrillation is the most common cardiac arrhythmia, affecting 8.5% of the general population in Hong Kong. Systemic embolization, and particularly stroke, is the most frequent major complication of atrial fibrillation. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atrial Fibrillation (AF), 3D Printing, Cost Benefit Analysis
- What is being tested?
- 3D-printed models of the left atrial appendage and Standard preoperative planning
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 184 participants
- Where
- 1 siteHong Kong
- Study dates
- 1 Oct 2017to 31 Jan 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥18 years
- Non-valvular atrial fibrillation
- CHA2DS2-VASc ≥2
- Absolute or relative contraindications to long-term oral anticoagulation (e.g. history of intracranial or life-threatening bleeding, HAS-BLED ≥3, triple anticoagulant therapy)
- Planned for LAAO procedure
Who cannot join
- Intracardiac thrombus is visualized by echocardiographic imaging
- An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present
- The LAA anatomy will not accommodate a device
- Any of the customary contraindications for other percutaneous catheterization procedures (e.g., patient size too small to accommodate TEE probe or required catheters) or conditions (e.g., active infection, bleeding disorder) are present.
- Known hypersensitivity to any portion of the device material or the individual components
- Comorbidities other than atrial fibrillation that required oral anticoagulation
- Suboptimal LAA image on TEE or CT that is inadequate for 3D modelling and printing
- Refusal to participate the study
Trial locations and contacts
1 site in 1 country.
Hong Kong1 site
Division of Cardiology, Department of Medicine and Therapeutics Faculty of Medicine, The Chinese University of Hong Kong
Hong Kong, New Territories, Sha Tin
About this study
Official title: 3D Printing Technology For Planning Left Atrial Appendage Occlusion: A Randomised Trial
Atrial fibrillation is the most common cardiac arrhythmia, affecting 8.5% of the general population in Hong Kong. Systemic embolization, and particularly stroke, is the most frequent major complication of atrial fibrillation. Long-term oral anticoagulation is recommended for most atrial fibrillation patients for prevention of embolism. However, such therapy is associated with an increased risk of bleeding and not all individuals are candidates for this therapy.
The left atrial appendage (LAA) is the usual source for clot that embolizes. Occlusion of the LAA ostium (LAAO) with percutaneous device in patients with nonvalvular atrial fibrillation has emerged as an alternative to anticoagulation for prevention of embolism.
Read more
Procedural success requires careful planning and understanding of the anatomy of LAA, as well as the interaction between the appendage and the occlusion device. However, complexity and variability of LAA anatomy exists and these anatomical variations among individuals poses challenges to accurately sizing and positioning the device. Certain anatomic variations of the appendage, for instance the presence of a sharp bend in the proximal or middle portion of the dominant lobe, or prominent pectinate muscles, pose particular challenge to device implantation and demands pre-specified implantation technique. Assessment of LAA anatomy relies on imaging, usually combining peri-interventional 2D transesophageal echocardiography (TEE) with fluoroscopy guidance and, less frequently, with pre-interventional computed tomography (CT). Because lobes of the LAA exist in different planes, imaging must be done in multiple planes to visualize the entire LAA. Even with advanced imaging, complete understanding the 3D geometry of the appendage is challenging, and the mechanical interaction between the device and the anatomy is difficult to predict or quantify.
The limitation of imaging in the assessment of LAA anatomy may lead to inaccurate device sizing. Over- or under-sizing increase the chance of pericardial effusion, incomplete occlusion, and device embolization. Incomplete occlusion of the LAA ostium is common and may jeopardise the procedural efficacy in embolism prevention. Device re-sizing during procedure prolongs procedural time as well as radiation exposure; moreover, device re-positioning within the appendage may cause inadvertent tissue injury and increase the risk of cardiac perforation. Indeed, procedural complication rate of LAAO remains fairly high in real-world practice.
3D printing (3DP) is a novel technology able to create a patient-specific model of any given anatomical portion of the heart for preoperative device testing and procedural simulation. The simulation "rehearsal" experience can enhance the operator's confidence, allowing the operator to anticipate difficulties before the actual intervention; this potentially reduces the procedural time (hence cost and radiation hazard), device re-sizing, the number of deployment attempts, and promotes procedural success.
The aim of this project is to evaluate the effect of 3D-printed patient-specific LAA model compared with standard imaging planning on procedural efficacy and safety of LAAO.
The project will be divided into two parts:
Part I Technical validation of 3D-printed LAA models Validation of anatomical accuracy and material properties of the 3D-printed LAA model will be conducted in 30 patients referred for clinically indicated surgical excision of the LAA.
Part II Randomised clinical trial on additive benefit of 3D printing for LAAO. The investigators will conduct a randomized, controlled, open-label, trial in 200 patients undergoing LAAO for stroke prevention in our hospital.
Eligible subjects will be randomly assigned by a computer program in a 1:1 ratio to either preoperative planning using 3D-printed LAA model (3D printing arm) or standard imaging planning alone (no-3D printing arm).
The investigators hypothesize that preoperative 3DP planning could help in finding the correct position within LAA, sizing the device and guiding the choice of the closure device despite the measurements provided by imaging alone.
- Conditions
- Atrial Fibrillation (AF), 3D Printing, Cost Benefit Analysis
- Being tested
- 3D-printed models of the left atrial appendage, Standard preoperative planning
- Keywords
- 3D printing, Left Atrial Appendage Occlusion, Atrial Fibrillation
- Medical subject headings
- Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
3D-printed models of the left atrial appendageDevice
Participants receive preoperative planning using patient-specific 3D-printed models of the left atrial appendage. This arm includes procedural simulation with different occlusion devices and sizes to optimize the intervention.
Standard preoperative planningOther
Participants undergo standard preoperative planning based solely on traditional imaging techniques, such as 2D/3D transesophageal echocardiography (TEE) and optionally computed tomography (CT).
| Study group | Role | What they receive |
|---|---|---|
| 3D printing arm | Active comparator | In the 3D printing arm, pliable 3D-printed LAA models will be created 1 week before the planned LAAO procedure using methodology described above. Preoperative procedural simulation will be conducted by testing different types (Watchman [Boston Scientific Inc.] and Amplatzer Amulet [St Jude Inc.]) and sizes (21-33mm for Watchman, 16-34mm for Amulet) of locally available LAAO devices on the 3D-printed pliable appendage model to determine the optimal device type and size that achieve proper positioning, stability, and complete occlusion of the ostium. Receives: Device: 3D-printed models of the left atrial appendage |
| Non 3D printing arm | Other | In the no-3D printing arm, standard preoperative planning based on preoperative imaging, namely, multi-planar 2D/3D TEE and, in selected cases at the physician's discretion, pre-interventional CT. Receives: Other: Standard preoperative planning |
What is being measured
The primary outcome is the main question the study is designed to answer.
To assess the rate of complete occlusion of the ostium
This will be determined by the absence of peri-device flow on color Doppler imaging or if the jet width is less than 1 mm.
Measured: The occlusion rate will be assessed during the procedure and at the 45-day TEE follow-up
Secondary outcomes (1)
Procedural complications
Pericardial effusion, cardiac perforation, device embolization, procedure-related stroke, bleeding.
Measured: During the procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2026
- Study start1 Oct 2017
- Primary completion31 Jan 2022
- Study completion31 Jan 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrial Fibrillation (AF)Studies of the same condition, open and under way.
- More trials run by Chinese University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 184 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chinese University of Hong Kong
- Sponsor type
- University, hospital or other
- Collaborators
- The University of Hong Kong
- Responsible party
- Principal investigator, Dr Alex PW Lee, Chinese University of Hong Kong
- Investigators
- Alex PW Lee, Professor, Principal investigator, Chinese University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07483008
- Sponsor's protocol ID
- 2017.397-T
- Status last verified
- Mar 2026
- First submitted
- 6 Mar 2026
- Last updated
- 19 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- 3D Printing Technology For Planning Left Atrial Appendage Occlusion: A Randomised Trial
- ClinicalTrials.gov ID
- NCT07483008
- Acronym / sponsor ID
- 2017.397-T
- Conditions
- Atrial Fibrillation (AF), 3D Printing, Cost Benefit Analysis
- Keywords
- 3D printing, Left Atrial Appendage Occlusion, Atrial Fibrillation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 184 participants (actual)
- Lead sponsor
- Chinese University of Hong KongUniversity, hospital or other
- Collaborators
- The University of Hong Kong
- Study start
- 1 Oct 2017 (actual)
- Primary completion
- 31 Jan 2022 (actual)
- Study completion
- 31 Jan 2022 (actual)
- First posted
- 19 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Atrial fibrillation is the most common cardiac arrhythmia, affecting 8.5% of the general population in Hong Kong. Systemic embolization, and particularly stroke, is the most frequent major complication of atrial fibrillation. Long-term oral anticoagulation is recommended for most atrial fibrillation patients for prevention of embolism. However, such therapy is associated with an increased risk of bleeding and not all individuals are candidates for this therapy.
The left atrial appendage (LAA) is the usual source for clot that embolizes. Occlusion of the LAA ostium (LAAO) with percutaneous device in patients with nonvalvular atrial fibrillation has emerged as an alternative to anticoagulation for prevention of embolism.
Procedural success requires careful planning and understanding of the anatomy of LAA, as well as the interaction between the appendage and the occlusion device. However, complexity and variability of LAA anatomy exists and these anatomical variations among individuals poses challenges to accurately sizing and positioning the device. Certain anatomic variations of the appendage, for instance the presence of a sharp bend in the proximal or middle portion of the dominant lobe, or prominent pectinate muscles, pose particular challenge to device implantation and demands pre-specified implantation technique. Assessment of LAA anatomy relies on imaging, usually combining peri-interventional 2D transesophageal echocardiography (TEE) with fluoroscopy guidance and, less frequently, with pre-interventional computed tomography (CT). Because lobes of the LAA exist in different planes, imaging must be done in multiple planes to visualize the entire LAA. Even with advanced imaging, complete understanding the 3D geometry of the appendage is challenging, and the mechanical interaction between the device and the anatomy is difficult to predict or quantify.
The limitation of imaging in the assessment of LAA anatomy may lead to inaccurate device sizing. Over- or under-sizing increase the chance of pericardial effusion, incomplete occlusion, and device embolization. Incomplete occlusion of the LAA ostium is common and may jeopardise the procedural efficacy in embolism prevention. Device re-sizing during procedure prolongs procedural time as well as radiation exposure; moreover, device re-positioning within the appendage may cause inadvertent tissue injury and increase the risk of cardiac perforation. Indeed, procedural complication rate of LAAO remains fairly high in real-world practice.
3D printing (3DP) is a novel technology able to create a patient-specific model of any given anatomical portion of the heart for preoperative device testing and procedural simulation. The simulation "rehearsal" experience can enhance the operator's confidence, allowing the operator to anticipate difficulties before the actual intervention; this potentially reduces the procedural time (hence cost and radiation hazard), device re-sizing, the number of deployment attempts, and promotes procedural success.
The aim of this project is to evaluate the effect of 3D-printed patient-specific LAA model compared with standard imaging planning on procedural efficacy and safety of LAAO.
The project will be divided into two parts:
Part I Technical validation of 3D-printed LAA models Validation of anatomical accuracy and material properties of the 3D-printed LAA model will be conducted in 30 patients referred for clinically indicated surgical excision of the LAA.
Part II Randomised clinical trial on additive benefit of 3D printing for LAAO. The investigators will conduct a randomized, controlled, open-label, trial in 200 patients undergoing LAAO for stroke prevention in our hospital.
Eligible subjects will be randomly assigned by a computer program in a 1:1 ratio to either preoperative planning using 3D-printed LAA model (3D printing arm) or standard imaging planning alone (no-3D printing arm).
The investigators hypothesize that preoperative 3DP planning could help in finding the correct position within LAA, sizing the device and guiding the choice of the closure device despite the measurements provided by imaging alone.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 3D printing arm | Active comparator | Device: 3D-printed models of the left atrial appendageIn the 3D printing arm, pliable 3D-printed LAA models will be created 1 week before the planned LAAO procedure using methodology described above. Preoperative procedural simulation will be conducted by testing different types (Watchman [Boston Scientific Inc.] and Amplatzer Amulet [St Jude Inc.]) and sizes (21-33mm for Watchman, 16-34mm for Amulet) of locally available LAAO devices on the 3D-printed pliable appendage model to determine the optimal device type and size that achieve proper positioning, stability, and complete occlusion of the ostium. |
| Non 3D printing arm | Other | Other: Standard preoperative planningIn the no-3D printing arm, standard preoperative planning based on preoperative imaging, namely, multi-planar 2D/3D TEE and, in selected cases at the physician's discretion, pre-interventional CT. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age ≥18 years
- Non-valvular atrial fibrillation
- CHA2DS2-VASc ≥2
- Absolute or relative contraindications to long-term oral anticoagulation (e.g. history of intracranial or life-threatening bleeding, HAS-BLED ≥3, triple anticoagulant therapy)
- Planned for LAAO procedure
Key exclusion criteria (8 listed)
- Intracardiac thrombus is visualized by echocardiographic imaging
- An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present
- The LAA anatomy will not accommodate a device
- Any of the customary contraindications for other percutaneous catheterization procedures (e.g., patient size too small to accommodate TEE probe or required catheters) or conditions (e.g., active infection, bleeding disorder) are present.
- Known hypersensitivity to any portion of the device material or the individual components
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 3D-printed models of the left atrial appendageParticipants receive preoperative planning using patient-specific 3D-printed models of the left atrial appendage. This arm includes procedural simulation with different occlusion devices and sizes to optimize the intervention. | Device | 3D printing arm |
| Standard preoperative planningParticipants undergo standard preoperative planning based solely on traditional imaging techniques, such as 2D/3D transesophageal echocardiography (TEE) and optionally computed tomography (CT). | Other | Non 3D printing arm |
Primary outcome
To assess the rate of complete occlusion of the ostium
Time frame: The occlusion rate will be assessed during the procedure and at the 45-day TEE follow-up
This will be determined by the absence of peri-device flow on color Doppler imaging or if the jet width is less than 1 mm.
1 secondary outcome
Procedural complications
Time frame: During the procedure
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Atrial Fibrillation (AF)
Active, not recruiting
VOLT CE Mark Study
Atrial Arrhythmia, Atrial Fibrillation
RecruitingObservational study
AI-Based Cardiac Analysis Using 12-Lead and 1-Lead ECG
Heart Failure, Atrial Fibrillation (AF)
Not yet recruiting
CATCH AF - Atrial Fibrillation Detection in Cryptogenic Stroke
Atrial Fibrillation (AF)
Not yet recruitingPhase 4
A Comparison of Beta-blockers and Calcium Channel Blockers in Atrial Fibrillation
Atrial Fibrillation (AF)
Not yet recruiting
Dual-Energy Lattice-Tip Assisted Marshall-Plan Strategy in Redo Persistent Atrial Fibrillation Ablation
Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alex PW Lee, Professor principal investigator
Chinese University of Hong Kong
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 3D-printed models of the left atrial appendage and Standard preoperative planning in people with Atrial Fibrillation (AF) and 3D Printing, run by Chinese University of Hong Kong at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To assess the rate of complete occlusion of the ostium (time frame: The occlusion rate will be assessed during the procedure and at the 45-day TEE follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2026.